Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Thursday. The firm set a “sell” rating on the stock.

Other equities research analysts also recently issued reports about the company. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price (down from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Up 20.8 %

Shares of NASDAQ SYRS opened at $0.09 on Thursday. Syros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $6.93. The company has a market cap of $2.48 million, a price-to-earnings ratio of -0.03 and a beta of 1.31. The business has a fifty day simple moving average of $0.17 and a 200-day simple moving average of $0.91.

Institutional Investors Weigh In On Syros Pharmaceuticals

Several hedge funds have recently bought and sold shares of SYRS. Exome Asset Management LLC lifted its stake in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after acquiring an additional 139,400 shares in the last quarter. Two Sigma Securities LLC purchased a new stake in Syros Pharmaceuticals in the 4th quarter worth about $25,000. Finally, GSA Capital Partners LLP purchased a new stake in Syros Pharmaceuticals in the 3rd quarter worth about $34,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.